Abstract
Human saliva contains a plethora of proteins whose presence and concentration can be monitored for diagnosis and progression of disease. Saliva has been extensively probed for the diagnosis of several systemic and infectious diseases because of the ease with which it can be collected. However, amylase, the most abundant protein found in saliva can obscure the detection of low-abundance proteins by MALDI-ToF MS (matrix-assisted laser desorption/ionization-time of flight mass spectrometry) and diminish the diagnostic utility of this specimen type. In the present study, we used a device to deplete salivary amylase from water-gargle samples through affinity adsorption. After depletion, profiling of the saliva proteome was performed by MALDI-ToF MS on gargle samples from subjects whose COVID-19 (coronavirus disease 2019) status was confirmed by NP (nasopharyngeal) swab RT-qPCR (reverse transcription polymerase chain reaction). Amylase depletion led to the enhancement of signal intensities of various peaks as well as the detection of previously unobserved peaks in the MALDI-ToF spectra. The overall specificity and sensitivity after amylase depletion was 100% and 85.17% respectively for detecting COVID-19. Our simple, rapid and inexpensive technique to deplete salivary amylase can be used to unmask spectral diversity in saliva by MALDI-ToF MS, reveal low-abundant proteins and aid in the establishment of novel biomarkers for diseases.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Institutional Review Board and Institutional Biosafety Committee of Northern Illinois University (approved on August 12, 2020, and revised on July 12, 2021, and August 11, 2022)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵# co-first authors
Data Availability
All de-identified data produced in the present study are available upon reasonable request to the authors.
Abbreviations
- ACE-2
- angiotensin-converting enzyme 2
- AUC
- area under the curve
- COVID-19
- coronavirus disease 2019
- DTT
- dithiothreitol
- HSA
- human serum albumin
- IDPH
- Illinois Department of Public Health
- IgA
- immunoglobulin A
- LC-MS
- liquid chromatography-mass spectrometry
- MALDI-ToF MS
- matrix-assisted laser desorption/ionization-time of flight mass spectrometry
- NP
- nasopharyngeal
- RNA
- ribonucleic acid
- ROC
- receiver operating characteristic
- RT-qPCR
- reverse transcriptase quantitative polymerase chain reaction
- S protein
- spike protein
- SARS-CoV-2
- severe acute respiratory syndrome coronavirus 2
- SDS-PAGE
- sodium dodecyl sulfate polyacrylamide gel electrophoresis
